Bortezomib (BTZ) represents a first-generation PI being approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of multiple myeloma (MM) and mantle cell lymphoma (MCL) [5]. The gene discussed is CASC3; the disease is Miyoshi myopathy.